Xu Xiang-Ming, Zhou Yong-Qing, Wang Ming-Hai
Laboratory of Cheung Kong Scholars Program for Biomedical Sciences at Institute of Infectious Diseases and Division of Neurosurgery, First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, People's Republic of China.
J Biol Chem. 2005 Jul 1;280(26):25087-94. doi: 10.1074/jbc.M414699200. Epub 2005 May 6.
The beta-catenin pathway plays a critical role in the pathogenesis of certain types of cancers. To gain insight into mechanisms by which altered receptor tyrosine kinases regulate cytoplasmic beta-catenin accumulation, the effect of an oncogenic receptor originated from Nantes (RON) variant on beta-catenin accumulation and the role of beta-catenin in RON-mediated tumorigenic activities were studied. In NIH3T3 cells harboring oncogenic variant RONDelta160, increased beta-catenin accumulation with tyrosine phosphorylation and nuclear translocation was observed. Overexpression of RONDelta160 also resulted in increased expression of beta-catenin target genes c-myc and cyclin D1. By analyzing cellular proteins that regulate beta-catenin stabilities, it was found that RONDelta160 activates the protein disheveled (DVL) and inactivates glycogen synthase kinase-3beta by Ser-9 residue phosphorylation. These effects were channeled by RONDelta160-activated PI 3-kinase-AKT pathways that are sensitive to specific inhibitors, such as wortmannin, but not to other chemical inhibitors. Silencing RONDelta160 expression by specific small interfering RNA blocked not only beta-catenin expression but also c-myc and cyclin D1 expression, suggesting that RON expression is required for the activation of the beta-catenin signaling pathway. Moreover, it was found that knockdown of the beta-catenin gene expression by small interfering RNA techniques reduces significantly the RONDelta160-mediated NIH3T3 cell proliferation, focus-forming activities and anchorage-independent growth. Thus, the oncogenic RON variant regulates beta-catenin stabilities through activation of DVL and inactivation of glycogen synthase kinase-3beta. The activated beta-catenin cascade is one of the pathways involved in tumorigenic activities mediated by the oncogenic RON variant.
β-连环蛋白通路在某些类型癌症的发病机制中起着关键作用。为深入了解受体酪氨酸激酶改变调节细胞质β-连环蛋白积累的机制,研究了源自南特(RON)变体的致癌受体对β-连环蛋白积累的影响以及β-连环蛋白在RON介导的致瘤活性中的作用。在携带致癌变体RONDelta160的NIH3T3细胞中,观察到β-连环蛋白积累增加,伴有酪氨酸磷酸化和核转位。RONDelta160的过表达还导致β-连环蛋白靶基因c-myc和细胞周期蛋白D1的表达增加。通过分析调节β-连环蛋白稳定性的细胞蛋白,发现RONDelta160激活了蛋白质无序化(DVL)并通过Ser-9残基磷酸化使糖原合酶激酶-3β失活。这些作用是由RONDelta160激活的PI 3-激酶-AKT通路介导的,该通路对诸如渥曼青霉素等特定抑制剂敏感,但对其他化学抑制剂不敏感。用特异性小干扰RNA沉默RONDelta160表达不仅阻断了β-连环蛋白表达,还阻断了c-myc和细胞周期蛋白D1表达,表明RON表达是激活β-连环蛋白信号通路所必需的。此外,发现通过小干扰RNA技术敲低β-连环蛋白基因表达可显著降低RONDelta160介导的NIH3T3细胞增殖、集落形成活性和非锚定依赖性生长。因此,致癌性RON变体通过激活DVL和使糖原合酶激酶-3β失活来调节β-连环蛋白稳定性。激活的β-连环蛋白级联反应是致癌性RON变体介导的致瘤活性所涉及的途径之一。